<DOC>
	<DOCNO>NCT00247780</DOCNO>
	<brief_summary>Atrial fibrillation ( AF ) common cardiac arrhythmia . Pulmonary vein isolation ( PVI ) leave atrium use radiofrequency energy new promise non-medical treatment patient symptomatic AF report success rate 65 % 90 % depend AF classification ablation procedure . However , risk recurrence lead suggestion improve clinical outcome tailor efficient ablation procedure . A prospective , randomise study 150 patient symptomatic AF refer PVI initiate patient allocated PVI alone ( 75 patient ) PVI additional ablation right atrium ( 75 patient ) . Patients undergo extensive monitoring heart rhythm follow-up document symptomatic asymptomatic AF atrial flutter . The presence asymptomatic AF PVI could potentially affect management anticoagulation therapy patient . The structural functional change atria PVI characterize new image technique ( Tissue Doppler Imaging ( TDI ) ) atria cardiac neurohormone . TDI may effective tool characterise change leave atrial function PVI . Neurohormones may provide new information regarding change leave atrial function clinical outcome PVI patient AF . We hypothesize : - Among patient predominant atrial fibrillation , PVI additional ablation right atrium associate well outcome , i.e . freedom symptomatic AF/atrial flutter overall . - Asymptomatic AF atrial flutter occur frequently PVI . - Left atrial volume systolic function correlate AF recurrence PVI . - Neurohormones level correlate AF recurrence PVI .</brief_summary>
	<brief_title>Cavotricuspid Isthmusblock Circumferential Pulmonary Vein Isolation Patients With Atrial Fibrillation</brief_title>
	<detailed_description>BACKGROUND : Atrial fibrillation ( AF ) common cardiac arrhythmia . Medical treatment often inefficient associate side effect . Pulmonary vein isolation ( PVI ) leave atrium use radiofrequency energy new promise non-medical treatment patient symptomatic AF report success rate 65 % 90 % depend AF classification ablation procedure ( 1 ) . Circumferential PVI appear superior ablation technique patient AF ( 2 ) . However , risk recurrence lead suggestion improve clinical outcome tailor efficient ablation procedure . Patients AF often coexist atrial flutter ( 3 ) , uncertain patient refer PVI benefit additional cavotricuspid isthmusblock ( CTI ) traditional ablation treatment atrial flutter . A recent study indicate PVI reduces AF atrial flutter eliminate share trigger pulmonary vein ( 4 ) . Other investigator show patient AF atrial flutter prior PVI high risk recurrent atrial flutter follow-up , successful PVI reduce risk recurrent atrial flutter ( 3 ) . The current approach lab perform additional CTI case document atrial flutter , CTI may potentially improve overall outcome ( freedom symptomatic arrhythmia ) patient without documented atrial flutter , especially since symptomatic period undocumented . A prospective , randomise study 150 patient symptomatic AF refer PVI initiate patient allocated PVI alone ( 75 patient ) PVI additional CTI ( 75 patient ) . Patients undergo extensive Holter monitor follow-up document symptomatic asymptomatic AF atrial flutter . Patients AF high incidence asymptomatic AF correlate increase risk tromboembolic complication ( 5 ) . The presence aymptomatic AF PVI could potentially affect management anticoagulation therapy patient . The structural functional change atria PVI describe study . To knowledge , Tissue Doppler Imaging ( TDI ) neurohormone ( NT-pro-BNP ANP ) previously use characterising leave atrial function PVI . New echocardiographic modality TDI introduce characterisation leave ventricle systolic function ischemic heart disease congestive heart failure . TDI use characterise global segmental atrial systolic function healthy individual ( 6 ) , TDI may effective tool characterise change leave atrial function PVI . Neurohormones produce left ventricle/atrium , patient AF elevated level due atrial stretch . Cardioversion AF sinus rhythm associate normalisation BNP/ANP level ( 7 ) , BNP independent risk factor develop AF patient mild congestive heart failure ( 8 ) . Neurohormones may therefore provide new information regarding change leave atrial function clinical outcome PVI patient AF . PURPOSE : - To investigate effect additional cavotricuspid isthmusblock patient AF refer circumferential pulmonary vein isolation . - To investigate incidence asymptomatic AF atrial flutter ablation extensive Holter monitoring . - To characterise left atrial volume function PVI echocardiographic assessment ( TDI ) measurement neurohormone ( NT-pro-BNP ANP ) . HYPOTHESIS : - Among patient predominant AF , PVI additional cavotricuspidal isthmusblock associate well outcome , i.e . freedom symptomatic AF/atrial flutter overall . - Asymptomatic AF atrial flutter occur frequently PVI . - Left atrial volume systolic function correlate AF recurrence PVI . - ANP/NT-pro-BNP level correlate AF recurrence PVI . DESIGN AND MATERIALS : A prospective , randomise study 150 patient referred PVI due symptomatic paroxysmal persistent AF . Patients randomise circumferential PVI ( 75 patient ) without ( 75 patient ) cavotricuspid isthmusblock right atrium . Follow period 12 month . Eighty include patient ( 40 paroxysmal 40 persistent AF ) undergo TDI-echocardiography neurohormonal measurement . METHOD : Admission : - History , physical examination , medication . - Echocardiographic characterisation leave atrial function volume leave ventricle systolic diastolic function ( TDI 80 patient ) . - NT-pro-BNP/ANP measurement ( 80 patient ) . - Questionnaire ( SF-36 ) . - Circumferential PVI . Patients randomise PVI without cavotricuspid isthmusblock . Ablation : One quadripolar 5-F catheter ( St. Jude Medical ) place right ventricular apex decapolar catheter ( Biosense Webster ) coronary sinus . Transseptal access leave atrium achieve use SL1 sheath ( St. Jude Medical ) . Three-dimensional map leave atrium constructed quadripolar D-curve mapping catheter ( 3.5-mm Navistar , Biosense Webster ) use non-fluoroscopic navigation system ( CARTO , Biosense-Webster ) . Patients heparinized use initial dose 100 IE/kg additional 1000 IE/hour . Radiofrequency energy deliver via 4-mm mapping catheter . Ablation line deploy circumferentially around pulmonary vein ( PV ) approximately 0.5 cm ostia . After ablation , remapping perform sinus rhythm pace coronary sinus . In case AF ablation , patient cardioverted sinus rhythm remapping . The criterion successful ablation elimination potential &gt; 0.1 mV within lesion determine voltage map . Ultimately , cavotricuspid ishtmusblock perform ablation catheter . The position catheter establish use fluoroscopy CARTO-mapping . Ishtmusblock verify double potential coronary sinus ( CS ) pacing , activation detour pace either side line , differential pacing technique . Follow-up : - 24 hour heart rhythm monitoring . - Clinical control 3,6 12 month - 1 week Holter monitoring 3 , 6 12 month - NT-pro-BNP/ANP measurement 3 12 month - Echocardiography 3 12 month 2D Echocardiography M-mode leave ventricle atrium parasternal view Left atrium enddiastolic endsystolic volume use Simpson biplane apical 4 2-chamber view Left ventricle enddiastolic endsystolic volume use Simpson biplane apical 4 2-chamber view Color M-mode Transmitral flow ( Pulsed Wave Doppler ) E- og A-peak velocity , E/A ratio og E-decelerationtime Atrial empty fraction = A velocity time integral ( VTI ) /total velocity time integral ( VTI ) Tissue Doppler echocardiography ( TDI ) Segmental atrial velocity amplitude right leave atrium Framerate 100 fps Five point apical 4-chamber projection : - 2 right atrium ( lateral annular superior ) - 3 leave atrium ( septal annular , superior lateral annular ) Three point apical 2 chamber view leave atrium ( posterior annular , superior annular anterior ) STATISTICS : The sample size calculated basis follow assumption : A type 1 error type 2 error 5 % 20 % , respectively , accept . The statistical power 80 % . Thirty-five percent patient AF coexist atrial flutter population refer PVI ( 3 ) . Patients undergo CTI due atrial flutter 10 % risk recurrence . During follow-up , 90 % versus 70 % ( without CTI ) patient expect free symptom relate atrial flutter . Based parameter , sample size 72 patient include group . Overall , 150 patient include due expect loss patient follow-up . In 2003 , ninety-five patient treat PVI Skejby Hospital increase 150 patient 2004 . The production expect increase follow year . PRACTICAL CONSIDERATIONS : The PhD protocol approve The Faculty Health Science University Aarhus Local Committee Ethics Aarhus . The study initiate December 2004 moment 8 patient include . The Institute Clinical Experimental Research University Hospital Aarhus donate 6 month salary Dr. Jacob Pontoppidan . The inclusion period 12 month . Patients follow 12 month . Finally , 12 month expect dataprocessing publication . At least 3 publication international peer-reviewed journal expect . The measurement neurohormone perform Department Clinical Biochemistry biochemical laboratory Department Nephrology , Skejby Hospital . The echocardiographic analysis include TDI perform Dr. Pontoppidan , experience technique . The electrophysiologists Department Cardiology , Skejby University Hospital Aarhus , perform ablation procedure describe .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Documented symptomatic paroxysmal persistent atrial fibrillation medical treatment proven inefficient related sideeffects . Prior cavotricuspid isthmus ablation ( atrial flutter ) Significant valvular heart disease Congestive heart failure ( NYHA class 34 ) Contraindications antithrombic treatment Warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Pulmonary vein isolation</keyword>
	<keyword>Tissue Doppler echocardiography</keyword>
</DOC>